OTCMKTS:CRPOF

Ceapro News Headlines

$0.51
+0.02 (+3.79 %)
(As of 09/16/2021 11:24 AM ET)
Add
Compare
Today's Range
$0.50
$0.51
50-Day Range
$0.45
$0.55
52-Week Range
$0.45
$0.73
Volume3,900 shs
Average Volume36,541 shs
Market Capitalization$39.77 million
P/E Ratio51.25
Dividend YieldN/A
Beta2.02

Media Mentions By Week

Ceapro Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CRPOF
News Sentiment

0.99

0.32

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CRPOF Articles
This Week

2

0

CRPOF Articles
Average Week

Get Ceapro News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRPOF and its competitors with MarketBeat's FREE daily newsletter.

Ceapro (OTCMKTS CRPOF) News Headlines Today

SourceHeadline
Short Interest in Ceapro Inc. (OTCMKTS:CRPOF) Decreases By 92.1%Short Interest in Ceapro Inc. (OTCMKTS:CRPOF) Decreases By 92.1%
americanbankingnews.com - September 14 at 3:56 PM
Ceapro Inc. (OTCMKTS:CRPOF) Short Interest UpdateCeapro Inc. (OTCMKTS:CRPOF) Short Interest Update
americanbankingnews.com - August 26 at 6:00 PM
Ceapro Inc. Reports 2021 Second Quarter and Six-Month Financial Results and Operational HighlightsCeapro Inc. Reports 2021 Second Quarter and Six-Month Financial Results and Operational Highlights
finance.yahoo.com - August 26 at 4:27 PM
Global Electric Vehicle Outlook 2021Global Electric Vehicle Outlook 2021
au.finance.yahoo.com - August 13 at 5:58 PM
Returns On Capital At Ceapro (CVE:CZO) Paint A Concerning PictureReturns On Capital At Ceapro (CVE:CZO) Paint A Concerning Picture
finance.yahoo.com - May 29 at 12:49 PM
Ceapro reports Q4 resultsCeapro reports Q4 results
seekingalpha.com - April 23 at 3:16 PM
Ceapro Inc.s (CVE:CZO) Has Had A Decent Run On The Stock market: Are Fundamentals In The Drivers Seat?Ceapro Inc.'s (CVE:CZO) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?
finance.yahoo.com - March 23 at 8:06 AM
Ceapro Inc. to Present at the H.C. Wainwright Global Life Sciences ConferenceCeapro Inc. to Present at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 3 at 9:43 AM
Is It Time To Consider Buying Ceapro Inc. (CVE:CZO)?Is It Time To Consider Buying Ceapro Inc. (CVE:CZO)?
finance.yahoo.com - February 6 at 2:10 PM
Ceapro Inc. to Present at NobleCon17Ceapro Inc. to Present at NobleCon17
finance.yahoo.com - January 14 at 5:07 PM
Ceapro Inc. to Present at the H.C. Wainwright BioConnect 2021 Virtual ConferenceCeapro Inc. to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
benzinga.com - January 8 at 8:09 AM
How Much Is Ceapros (CVE:CZO) CEO Getting Paid?How Much Is Ceapro's (CVE:CZO) CEO Getting Paid?
finance.yahoo.com - December 23 at 1:09 PM
Returns On Capital At Ceapro (CVE:CZO) Paint An Interesting PictureReturns On Capital At Ceapro (CVE:CZO) Paint An Interesting Picture
finance.yahoo.com - September 14 at 9:34 AM
Ceapro Inc. Announces Publication of Positive Results from Study Evaluating Avenanthramides in Exercise-Induced InflammationCeapro Inc. Announces Publication of Positive Results from Study Evaluating Avenanthramides in Exercise-Induced Inflammation
finance.yahoo.com - August 4 at 12:52 PM
Can Mixed Fundamentals Have A Negative Impact on Ceapro Inc. (CVE:CZO) Current Share Price Momentum?Can Mixed Fundamentals Have A Negative Impact on Ceapro Inc. (CVE:CZO) Current Share Price Momentum?
finance.yahoo.com - July 15 at 1:34 PM
Ceapro Inc. Expands Collaborative Research Program with McMaster University to Develop Inhalable Therapeutic for COVID-19Ceapro Inc. Expands Collaborative Research Program with McMaster University to Develop Inhalable Therapeutic for COVID-19
finance.yahoo.com - May 26 at 1:10 PM
Ceapro Inc. Reports Fourth Quarter and Full Year 2019 Results and HighlightsCeapro Inc. Reports Fourth Quarter and Full Year 2019 Results and Highlights
finance.yahoo.com - April 16 at 9:07 AM
Ceapro Inc. to Present at the April 2020 Virtual Investor SummitCeapro Inc. to Present at the April 2020 Virtual Investor Summit
finance.yahoo.com - April 15 at 8:13 AM
If You Had Bought Ceapro (CVE:CZO) Stock Three Years Ago, Youd Be Sitting On A 87% Loss, TodayIf You Had Bought Ceapro (CVE:CZO) Stock Three Years Ago, You'd Be Sitting On A 87% Loss, Today
finance.yahoo.com - March 27 at 2:31 PM
If You Had Bought Ceapro (CVE:CZO) Stock Three Years Ago, You'd Be Sitting On A 87% Loss, TodayIf You Had Bought Ceapro (CVE:CZO) Stock Three Years Ago, You'd Be Sitting On A 87% Loss, Today
finance.yahoo.com - March 27 at 2:31 PM
Ceapro Inc. to Present at Noble Capital Markets’ 16th Annual Investor ConferenceCeapro Inc. to Present at Noble Capital Markets’ 16th Annual Investor Conference
finance.yahoo.com - February 10 at 12:34 PM
Ceapro Inc. Announces Approval from Health Canada for Protocol Expansion of Current Clinical Study Assessing ...Ceapro Inc. Announces Approval from Health Canada for Protocol Expansion of Current Clinical Study Assessing ...
www.globenewswire.com - February 5 at 8:14 AM
Ceapro Inc. Announces Approval from Health Canada for Protocol Expansion of Current Clinical Study Assessing Beta Glucan as a Cholesterol-Lowering AgentCeapro Inc. Announces Approval from Health Canada for Protocol Expansion of Current Clinical Study Assessing Beta Glucan as a Cholesterol-Lowering Agent
finance.yahoo.com - February 5 at 8:14 AM
Ceapro Inc. Secures DTC Eligibility for Publicly Traded Shares Under Ticker OTCQZ: CRPOFCeapro Inc. Secures DTC Eligibility for Publicly Traded Shares Under Ticker OTCQZ: CRPOF
finance.yahoo.com - January 31 at 12:17 PM
How Does Investing In Ceapro Inc. (CVE:CZO) Impact The Volatility Of Your Portfolio?How Does Investing In Ceapro Inc. (CVE:CZO) Impact The Volatility Of Your Portfolio?
finance.yahoo.com - January 27 at 1:56 PM
Ceapro Inc. Announces Publication of Results for a New PGX Processed Chemical Complex in the Journal of Supercritical FluidsCeapro Inc. Announces Publication of Results for a New PGX Processed Chemical Complex in the Journal of Supercritical Fluids
finance.yahoo.com - December 17 at 8:26 AM
How Much Did Ceapro Inc.'s (CVE:CZO) CEO Pocket Last Year?How Much Did Ceapro Inc.'s (CVE:CZO) CEO Pocket Last Year?
finance.yahoo.com - November 18 at 9:01 AM
Ceapro Inc. Announces Issuance of U.S. and European Patent for Flagship Product, AvenanthramidesCeapro Inc. Announces Issuance of U.S. and European Patent for Flagship Product, Avenanthramides
finance.yahoo.com - October 29 at 9:11 AM
Did You Manage To Avoid Ceapro's (CVE:CZO) Devastating 80% Share Price Drop?Did You Manage To Avoid Ceapro's (CVE:CZO) Devastating 80% Share Price Drop?
finance.yahoo.com - October 3 at 8:41 AM
Ceapro to Present PGX Technology at the 3rd International Symposium on Pharmaceutical Engineering ResearchCeapro to Present PGX Technology at the 3rd International Symposium on Pharmaceutical Engineering Research
markets.businessinsider.com - September 25 at 3:53 PM
Ceapro Inc. to Present at the Fall Investor Summit in New YorkCeapro Inc. to Present at the Fall Investor Summit in New York
markets.businessinsider.com - September 10 at 9:10 AM
Ceapro Inc. Reports 2019 First Quarter Financial Results and HighlightsCeapro Inc. Reports 2019 First Quarter Financial Results and Highlights
markets.businessinsider.com - May 23 at 11:13 AM
Ceapro Inc. Announces Receipt of Site License from Health CanadaCeapro Inc. Announces Receipt of Site License from Health Canada
www.nasdaq.com - May 15 at 9:28 PM
Ceapro Inc. Announces Positive Key Findings from Three Oral Presentations Given at European Meeting on Supercritical FluidsCeapro Inc. Announces Positive Key Findings from Three Oral Presentations Given at European Meeting on Supercritical Fluids
www.globenewswire.com - April 15 at 9:20 AM
Ceapro Inc. Reports Fourth Quarter and Full Year 2018 Results and HighlightsCeapro Inc. Reports Fourth Quarter and Full Year 2018 Results and Highlights
markets.businessinsider.com - April 11 at 4:23 PM
Ceapro Inc. Announces Three Abstracts Selected for Oral Presentation at the 17th European Meeting on Supercritical Fluids (EMSF 2019)Ceapro Inc. Announces Three Abstracts Selected for Oral Presentation at the 17th European Meeting on Supercritical Fluids (EMSF 2019)
globenewswire.com - February 26 at 12:09 PM
Get Ceapro News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRPOF and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 9/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.